Ranitidine Faces New Safety Checks in India Amid Cancer Risk Concerns
New Delhi: Popular acidity drug Ranitidine is back in the spotlight after India’s top drug regulator issued a nationwide alert over the presence of NDMA, a potential cancer-causing impurity. The Central Drugs Standard Control Organisation (CDSCO) has asked all state and Union Territory drug regulators to ensure that manufacturers monitor NDMA (N-nitrosodimethylamine) levels in both…
